Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2021 Earnings Presentation
12 slides from Indivior Pharmaceuticals's earnings presentation, Apr 29, 2021
Slide 1: Indivior PLC Q1 2021 Results
Indivior PLC Q1 2021 Results April 29, 2021
Slide 2: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 3: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 4: Q1 2021 key messages: Executing on our Strategic Priorities
Q1 2021 key messages Executing on our Strategic Priorities Good start to FY 2021 – continued SUBLOCADE® progression; overall net revenue and profit* improvement Strong financial position maintained – grew cash balance to $945m FY 2021“Base Case” guidance reconfirmed * On an Adjusted basis. See Appen
Slide 5: Strategic Priorities report card: Q1 2021
Strategic Priorities report card: Q1 2021 1 2 3 4 Grow SUBLOCADE® >$1 bil. Diversify Revenue Build Our Pipeline Optimize Operating Model • SUBLOCADE® US Labeling: All • Cash: $945m (+$87m vs. • Q1 21 NR: $43m (+10% vs. • SUBUTEX® Prolonged additional label submissions FYE 2020) Q4 20; +48% vs. Q1 20
Slide 6: Current US environment: significant support and funding for treatment
Current US environment: significant support and funding for treatment $3 bil. in new funding for Substance Use Disorders (SUD) and mental health treatment from American Rescue Plan Act $10.7 bil. requested in Biden HHS budget to combat opioid epidemic (+$3.9 bil. vs. 2021) Biden-Harris drug policy f
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Income statement Q1
Income statement* Q1 Highlights 2021 2020 % Adjusted Adjusted change Net Rev.: Reflects strong SUBLOCADE® growth, underlying US BMAT market growth ($ in mil.) along with relatively stable SUBOXONE® Film share in US; ROW net rev. up modestly on Net Revenue $180 $153 +18% favorable currency translatio
Slide 9: Cash & borrowing position
Cash & borrowing position Q1 FY • Net cash growth to $711m at end of Q1 21 ($ in mil.) 2021 2020 reflects: ✓ Timing of government rebate payables Cash & Cash Equivalents $945 $858 ✓ $26m of returned collateral from surety bond provider • Maintaining prudent and balanced cash stance: Current Borrowin
Slide 10: FY 2021 guidance reiterated
FY 2021 guidance reiterated FY 21 Guidance(1) ($ in mil.) FY 2021 NR Assumptions • Base case NR: Currently assumes the operating backdrop Total Base Case NR Up to $625m will improve in H2 2021, as COVID-19 pandemic • SUBLOCADE NR base case • $185m to $210m • PERSERIS NR base case • $17m to $20m rest
Slide 11: Appendix
Appendix So INDIVIOR
Slide 12: Income statement: Q1 2021 vs. Q1 2020
Income statement: Q1 2021 vs. Q1 2020 Q1 2021 Q1 2020 Δ Q1 2021 Q1 2021 Y-o-Y Q1 2020 Q1 2020 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 180 180 +18% 153 153 Cost of Sales (32) (32) (23) 7 (1) (16) Gross Profit 148 148 +8% 130 137